# Glycosylation Matters: Network Pharmacology-Based and Molecular Docking Analysis of Resveratrol Glycosylated Derivatives on Parkinson’s Disease

## TL;DR

This study explores how glycosylated forms of resveratrol may improve its effectiveness in treating Parkinson’s Disease by enhancing molecular interactions with key targets.

## Contribution

The novelty lies in comparing glycosylated resveratrol derivatives with resveratrol itself using network pharmacology and molecular docking for Parkinson’s Disease.

## Key findings

- Glycosylated resveratrol derivatives showed stronger binding affinities to PD-related targets than resveratrol.
- TNF-α, PPARγ, and ERBB2 were identified as key targets with high binding potential for glycosylated derivatives.
- Resveratrol retained better overall pharmacokinetic properties despite glycosylated derivatives having improved solubility.

## Abstract

Resveratrol (RV), a natural polyphenol, has been extensively
studied
for its neuroprotective potential in Parkinson’s Disease (PD),
but its clinical translation is limited by poor bioavailability and
rapid metabolism. Glycosylated derivatives, including polydatin and
resveratrol-3-α-glucoside, have been proposed to improve the
solubility and stability. This study compared the pharmacokinetic
properties of RV and its derivatives and examined their molecular
interactions with PD-related targets. ADMET (Absorption, Distribution,
Metabolism, Excretion, and Toxicity) analysis showed that, despite
improved solubility, RV retained a more favorable overall pharmacokinetic
profile. Target prediction combined with Gene Ontology (GO) enrichment,
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and
protein–protein interaction (PPI) network construction identified
50 potential targets, with 11 prioritized for molecular docking. Glycosylated
derivatives exhibited binding affinities for all targets stronger
than those of RV, with TNF-α, PPARγ, and ERBB2 highlighted
as key candidates. These findings indicate that RV glycosylation may
enhance therapeutic potential for PD treatment by promoting stronger
molecular interactions with critical targets, though in vivo validation remains necessary.